Australian (ASX) Stock Market Forum

OSX - Osteopore Limited

Jump to new
System

System

Joined
27 June 2010
Posts
4,147
Reactions
309
Osteopore was founded in 2003 and is a bone regeneration company that, through a combination of 3D printing and bioresorbable material, manufactures devices that biomimic the cancellous bone microarchitecture that facilitates the natural stages of bone healing.

Osteopore's products are fabricated in-house using proprietary 3D printing technology that is precise and allows for customisation of shape and geometry.

Following receipt of US Food and Drug Administration (FDA) approval in 2006 and CE-Mark approval in 2009 (and reapproval in 2017), Osteopore has successfully commercialised three products, 'Osteoplug', 'Osteomesh' and 'Osteostrip' and has sold over 20,000 units to hospitals in Singapore, South Korea, Vietnam and Malaysia since inception.

It is anticipated that OSX will list on the ASX during September 2019.

http://www.osteopore.com
 
OSX debuted on Monday 23 September 2019. I found out about it from the news:

https://www.smh.com.au/business/com...opore-soars-on-asx-debut-20190923-p52u2c.html

As the article states, the company made a loss of $870k last year. However the technology seems promising.

When I checked that morning the SP was $0.71. It closed today at $1.03. I don't know much about it other than what's in the news, so would appreciate anyone else's insights into this company and this field.
 
up more than 270% during day, to close at 83c, or some 108% better. News of a deal, distribution into US market. The first one, to 6 states.

Bioplate will cover all technical support requirements for Osteopore’s products.

The agreement with Bioplate is Osteopore’s first distribution agreement since the company’s IPO in 2019. Bioplate has over 20 years of experience in providing cranial fixation solutions and will provide Osteopore with an established network of health professionals, hospitals and health services in the US.

According to Osteopore, the graft substitute market is worth around US$4 billion, with sales of permanent implants estimated at over US$100 million annually. Osteopore believes that penetrating the US market is a key strategic objective, with US demand accounting for a large portion of the global demand.

What does Osteopore do?
Osteopore is an Australian and Singapore-based medical technology company that has commercialised a range of patented, 3D printed bioresorbable products. These 3D printed implants act as a scaffold for bone growth and can be used across various surgeries. As opposed to traditional bone grafts, Osteopore’s implants naturally dissolve over time, leaving only health bone tissue.

According to Osteopore, the company’s protective implants can reduce post-surgery complications by reducing the risk of secondary infections. All 3 of Osteopore’s products (Osteoplug, Osteomesh and Osteostrip) have received FDA approval in the US and are being sold to hospitals around the globe.

Earlier this year, Osteopore reported a 60% increase in revenue for the quarter ending March 2020. The company generated $321,00 in revenue for the quarter whilst also receiving approval from the Australian Therapeutic Goods Administration for several of its craniofacial products.
 
Be Careful Venturing Into The Wild West

Speculation had quickly evolved into the “greater fool” theory – a case of buying something, anything in the hope that a bigger fool than you will buy it off you for a higher price...

Sadly, this version of stock market musical chairs has only accelerated with greater levels of stupidity where daily I am witnessing traders torch money at faster rates....

"Osteopore (OSX) was another classic on Thursday. After announcing a deal with a distributor in the USA, its share price surged from 40c to almost $1.50 in the opening hour. So vague was the announcement, the Company received a please explain from the ASX. That explanation of only having sales of less than $5000and not being able to give any indication of what sales may look like with this new distributor, clearly took the wind out of the sails of OSX when it resumed trading. A massive gap lower in price and further deterioration shows how important it is to know what you are buying and what price you are really paying."

20200703_gt_b-300x225.png


https://www.sharecafe.com.au/2020/07/03/be-careful-venturing-into-the-wild-west/

(don't hold; merely post about it)
 
I bought some of these. It's like a bung for your head. Worth a go. Something's got stop the rot.
 
bit more marketing fluff from Aus business review
Osteopore’s 3D-printed bioresorbable implants have the potential to revolutionise surgical procedures globally, reducing complications and improving patient outcomes.

Natural tissue regeneration specialist Osteopore (ASX:OSX) is changing the way surgery is conducted globally, improving patient outcomes while working to reduce medical costs.

Osteopore’s new executive chairman Mark Leong says surgical specialists in Australia and globally are increasingly seeking to harness the body’s natural regenerative capabilities, rather than rely on artificial replacement parts or bone grafts, which have limitations that regenerative implants can overcome.

“With bone grafts there is potential for pain at the harvest site and your body may even absorb the graft with no regeneration,” Leong says.

“Permanent implants are non-biodegradable with reported instances of infections, post-surgical complications and are difficult to micro-adjust for a better fit during the medical procedure.”
Click to expand...
Have got a low ball bid in if it tanks again.
Mick
 
Wo, up 43% today.
My lowball bid is finally in the money.
Not sure why, did not see any announcements.
But I'll take it.
Mick
 
And just as quickly it gets dumped.
Released Qtrly and yearly results.
Big improvements on last years disastrous cutbacks due to Covid closing elective surgery for chunks of the year.
Market very unimpressed, must have expected more.
Best part is the expansion into international markets, but coming from a smallish base.
Will continue to hold.
Mick
 
OSX has been pretty volatile.
Last week I had a smallish portion of my 0.21 sell taken out at the open, then it fell back as low as 0.16, so did not think the rest would be taken out anytime soon.
Surprisingly, it had another run over the past few days, but when I looked at the open this morning, there was now another order ahead of me in the queue at 0.21.
Leaves me scratching me head as to what circumstances the ASX allows another order to be ahead of me in the queue.
Strange goings on.
Mick
 
Lots of moolah won and lost on this fella today ........ been on the wrong side of a couple of these over the years ... fortunately I have learned not to chase short term day trading "dreams" ... It is the realm of "insider" knowledge ... if you aren't on the "inside" knowledge, stay out!

1711519505176.png
 
barney said:
Lots of moolah won and lost on this fella today ........ been on the wrong side of a couple of these over the years ... fortunately I have learned not to chase short term day trading "dreams" ...
Click to expand...
Highlights
1. Osteopore secures Singaporean and Vietnamese market approvals to supply its groundbreaking orthopaedic products
2. Regulatory clearance includes a suite of off-the-shelf products for High Tibial Osteotomy, bone grafting, and customisable implants for complex bone loss
3. Validates Osteopore's orthopaedic products in the Singaporean and Vietnamese markets, strengthening its positioning in the high-growth global orthopaedic market
4. In 2020-21, HTO procedures doubled in Singapore, particularly amongst 40-60- year-olds
5. The HTO market is expected to grow at a CAGR of 9.2%, while the general bone grafting market is projected to expand at a CAGR of 2.3%

.... and then , not long afterwards
1. the voluntary suspension is requested due to unexpected delays in completing the 31 December 2023 Annual Report due to compiling information requested by the Company’s auditors. The Directors do not consider that trading of the Company’s securities should occur while the Annual Report remains un-lodged.
2. it anticipates the voluntary suspension will remain in place until the earlier of the commencement of normal trading on Tuesday, 30 April 2024, or until the 31 December 2023 Annual Report is lodged with the ASX..
.
Screenshot_20240329-110939_Drive.jpg
.
Screenshot_20240329-110907_CommSec.jpg
.
 
Dona Ferentes said:
Highlights
1. Osteopore secures Singaporean and Vietnamese market approvals to supply its groundbreaking orthopaedic products
2. Regulatory clearance includes a suite of off-the-shelf products for High Tibial Osteotomy, bone grafting, and customisable implants for complex bone loss
3. Validates Osteopore's orthopaedic products in the Singaporean and Vietnamese markets, strengthening its positioning in the high-growth global orthopaedic market
4. In 2020-21, HTO procedures doubled in Singapore, particularly amongst 40-60- year-olds
5. The HTO market is expected to grow at a CAGR of 9.2%, while the general bone grafting market is projected to expand at a CAGR of 2.3%

.... and then , not long afterwards
1. the voluntary suspension is requested due to unexpected delays in completing the 31 December 2023 Annual Report due to compiling information requested by the Company’s auditors. The Directors do not consider that trading of the Company’s securities should occur while the Annual Report remains un-lodged.
2. it anticipates the voluntary suspension will remain in place until the earlier of the commencement of normal trading on Tuesday, 30 April 2024, or until the 31 December 2023 Annual Report is lodged with the ASX..
.
View attachment 173646.
View attachment 173647.
Click to expand...
Good to see auditors doing their job.
 
In case you thought March 2024 was an aberration, OSX has done it all over again for April:
They announced first in-human clinical trials commencement, 23rd April. 1st patient of 12 treated. This announcement was NOT flagged as price-sensitive ... hmmmm, how curious.
Wild spasms of share price. UP-diddly-up-up (intra-day high of $0.55c, then down some (after a speeding ticket from the ASX), and up diddly-up-up again today.
I get that it's a small cap, so a bit pf progress can make a big difference. Even at $0.40c, it's still under $5 mill market cap.

But this stock has a history of ... shall we say ... curious behaviour.

Caution, Will Robinson...
Discl: I don't hold, and have not.

1714119694258.jpeg
 
Purple XS2 said:
In case you thought March 2024 was an aberration, OSX has done it all over again for April:
They announced first in-human clinical trials commencement, 23rd April. 1st patient of 12 treated. This announcement was NOT flagged as price-sensitive ... hmmmm, how curious.
Wild spasms of share price. UP-diddly-up-up (intra-day high of $0.55c, then down some (after a speeding ticket from the ASX), and up diddly-up-up again today.
I get that it's a small cap, so a bit pf progress can make a big difference. Even at $0.40c, it's still under $5 mill market cap.

But this stock has a history of ... shall we say ... curious behaviour.

Caution, Will Robinson...
Discl: I don't hold, and have not.

View attachment 175623
Click to expand...
Weird, what is an in human trial? Why don't they call it a phase 2 trial?
I agree with you Purple, Caution Will Robertson!
 
Last edited:
Further to my comment above that Ostepore is low-cap, $5 miil ...
... without having acquainted myself with the recent fact that OSX recently announced a right issue of 10 to 1, such that existing holders as of the record date last month, could acquire ten new shares for each share held, at an issue price of $0.29c.

Which makes it all the more bizarre that anyone would want to pay upwards of 35 -40 cents, no matter how bubbly the ride.

Assuming the rights are taken up in their entirety, it would soon make Osteopore more like a $50 mill cap. But until such time as the rights expire and the final size of the issue is determined, the company will still appear as a circa $5mill cap.

Which under the circumstances is quite obfuscating.
 
I really need to proof-read my posts: Osteopore's right issues was NOT for $0.29c per new share, it was 1/10 of that:
$0.029 cents per new share - at a 10 for 1 rights for shares held back at the record date.
Which explains the sharp drop in today's SP, from $0.31 down to close today at $0.125

I can only conclude the same innumerate dyslexia prompted some of the overblown buying in recent days.
With the new share rights taken up at over 95%, the total number of shares on issue is now 109 million.
Provided I've got the numbers right this time. :oops:
 
Top